Ronny Renfurm

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Philippe Gabríel Steg, Shamir R. Mehta, J. Wouter Jukema et al. · European Heart Journal · 2011 · 185 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

Vlado Perkovic, Jonathan Barratt, Brad H. Rovin et al. · New England Journal of Medicine · 2024 · 162 citations

Medicine, Immunology, Nephrology +14

The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients

Priyanka Priyanka, Alexander Zarbock, Junichi Izawa et al. · Journal of Thoracic and Cardiovascular Surgery · 2020 · 131 citations · Full text

Medicine, Nephrology, Surgery +15

Atrasentan in Patients with IgA Nephropathy

Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan et al. · New England Journal of Medicine · 2024 · 99 citations · Full text

Medicine, Nephrology, Pharmacotherapy +8

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial

Dick de Zeeuw, Ronny Renfurm, George L. Bakris et al. · The Lancet Diabetes & Endocrinology · 2018 · 48 citations · Full text

Medicine, Nephrology, Pharmacotherapy +13